are now very widely used in the clinical laboratory, either because no other type of assay system is feasible or because they are often the most effective and suitable of the possible analytical methods. The last decade has seen the development and refinement of many new immunoassay reagents and systems. The major trend has been away from liquid-phase assays involving radioisotopic labels, towards fast homogeneous or solid-phase assays capable of operation anywhere; and towards precise and reliable nonisotopic, automated or semi-automated laboratory assays, often with detection limits measured in pico-or attomoles. The use of monoclonal antibodies is now widespread, and the methodologies of labels and of solid-phase components are much more sophisticated. New assay formulations, novel homogeneous systems, immunosensors, free-analyte assays, the importance of thorough validation and of interfenng substances, and future trends are discussed.
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If a quadravalent Lvidin bridge is used, the possibility of large final comlexes could be represented as sp-Ab-Ag-Ab-biotin-avi-[in- [biotin-enzyme] Figure  2A ). Enzymes in labels have increased in popularity, from use in about 20% of new assays to about 35%. Figure  2B shows that for new enzyme-labeled assays horseradish peroxidase is used about 50% of the time and alkaline phosphatase about 25% of the time. At present, no other enzyme looks set to seriously rival either of these two with respect to widespread general use. The popularity of horseradish peroxidase is at least partly due to its high turnover number, the variety of sensitive assay systems available (see Table 3 Figure  3A ). Of the new assays or assay systems described in Clinical Chemistry, 10% to 20% require no separation step, a fraction that has remained constant over the past decade ( Figure  3A) . Therefore, most immunoassays, particularly those designed to operate in the picomole range or lower, involve a distinct separation step or even a series of such steps (Table  4) . A wide range of solid phases are commonly used ( Figure  3B , Table 4 ) and are also used in about 70% of new assays developed ( Figure  3M . In some solid-phase assays the use of "first" (38) ( all solid-phase separation methods The general criteria for the inclusion of data were the same as for Fig. 1 
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